Angiogenesis inhibitors in clinical development; where are we now and where are we going? - Wikidata - wikimedia - TriplyDB

Angiogenesis inhibitors in clinical development; where are we now and where are we going?

Angiogenesis inhibitors in clinical development; where are we now and where are we going?

http://www.wikidata.org/entity/Q35622433

about

Development of a highly-potent anti-angiogenic VEGF8-109 heterodimer by directed blocking of its VEGFR-2 binding site Polymeric Nanostructures for Imaging and Therapy Development of a one-step embryonic stem cell-based assay for the screening of sprouting angiogenesis.The aryl hydrocarbon receptor is required for induction of p21cip1/waf1 expression and growth inhibition by SU5416 in hepatoma cells.Antagonistic VEGF variants engineered to simultaneously bind to and inhibit VEGFR2 and alphavbeta3 integrin The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents.Hypoxia in head and neck cancer in theory and practice: a PET-based imaging approach Intravenous administration of anti-vascular endothelial growth factor humanized monoclonal antibody bevacizumab improves articular cartilage repair N⁴-(3-Bromophenyl)-7-(substituted benzyl) pyrrolo[2,3-d]pyrimidines as potent multiple receptor tyrosine kinase inhibitors: design, synthesis, and in vivo evaluation.Overexpression of Trps1 contributes to tumor angiogenesis and poor prognosis of human osteosarcoma.Novel tricyclic indeno[2,1-d]pyrimidines with dual antiangiogenic and cytotoxic activities as potent antitumor agents.Molecularly-targeted therapies for non-small cell lung cancer.Metronomic low-dose chemotherapy as antiangiogenic therapeutic strategy for cancer.Anti-angiogenic treatment of gastrointestinal malignancies.Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo.Antiangiogenic cancer therapies get their act together: current developments and future prospects of growth factor- and growth factor receptor-targeted approaches.Relationship between inducible nitric oxide synthase expression and angiogenesis in primary gallbladder carcinoma tissue.Antiangiogenic therapy in human gastrointestinal malignancies.Recent advances in targeted therapies for colorectal cancer.The therapeutic potential of a series of orally bioavailable anti-angiogenic microtubule disruptors as therapy for hormone-independent prostate and breast cancers.Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer.Mitochondrial D-loop mutations and deletion profiles of cancerous and noncancerous liver tissue in hepatitis B virus-infected liver Expression patterns of angiogenic and lymphangiogenic factors in ductal breast carcinoma in situ.VEGF/VEGFR signalling as a target for inhibiting angiogenesis.Tumor recovery by angiogenic switch from sprouting to intussusceptive angiogenesis after treatment with PTK787/ZK222584 or ionizing radiation The in vivo properties of STX243: a potent angiogenesis inhibitor in breast cancer.Angiogenesis and vascular targeting: relevance for hyperthermia.Advances in experimental and translational research in the treatment of hepatocellular carcinoma Molecular Biomarkers of Response to Antiangiogenic Therapy for Cancer.Receptor tyrosine kinase inhibitors: molecularly targeted drugs for veterinary cancer therapy.Kinase dysfunction and kinase inhibitors.Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) in Preclinical Studies of Antivascular Treatments.Investigational platelet-derived growth factor receptor kinase inhibitors in breast cancer therapy.Tyrosine kinase inhibitors as reversal agents for ABC transporter mediated drug resistance.Nanomedicine in management of hepatocellular carcinoma: Challenges and opportunities.Scl gene construction, expression and effect on hemangioma.Growth inhibition of malignant melanoma by intermediate frequency alternating electric fields, and the underlying mechanisms.Regulation of vascular endothelial growth factor signaling by miR-200b.Indolinones and anilinophthalazines differentially target VEGF-A- and basic fibroblast growth factor-mediated responses in primary human endothelial cells.Predictive value of Smac, VEGF and Ki-67 in rectal cancer treated with neoadjuvant therapy.

P2860

Q24302190-7588EEA4-DC86-4626-9602-8A9E16E667C1 Q30372383-BA00A4DF-1D44-45EF-8747-7C0753EBFAD2 Q33282216-5D4724BB-14D8-4BC3-8D1C-7CF64DCDDADE Q33648812-3B7329D3-6944-4D95-81EA-7B108D4B5346 Q33985577-A61A8C68-2D20-4BEE-A2AA-7C6816A62D4E Q34122191-A45E05B2-8282-4409-97CA-ED96D13D13CC Q34151551-9FDAFDE6-30B3-46BD-B05A-667BB5186831 Q34346264-34AF6CBB-3F3B-43DD-BA5B-7C231286559E Q35848191-625B9951-8C46-47F2-910B-15FBF6FAC337 Q36071047-4A355721-5C26-447D-A7E4-7F21A5EB6D55 Q36096646-62657BC3-BC77-4B21-A23B-31734DEB8DB5 Q36326239-1FA39346-AA1B-4DD3-AB8D-5C2AEF23DEF0 Q36341538-6E21FBC6-EC57-4236-B604-92EAA751FB3C Q36353516-74B2A2B2-74CA-4E86-9874-63EC73F6091F Q36388501-2D86A2AE-3559-4E97-89CD-A6B54C8156BC Q36397316-55D8D477-E308-4940-B7E7-3A3C32846B18 Q36474169-94F93C52-2708-4D1A-9474-C0F07CC3DA92 Q36591067-37DCC818-D562-47C4-A762-0B33FF7DB8FA Q36597888-E0A333EA-C72F-4892-98FF-3A2DE0B321F0 Q36610771-1752B752-02EB-41D6-A4EE-99581B84E4B6 Q36614881-F296B5F0-CC89-4001-A389-86787EFAE83B Q36616605-96353434-FD10-4773-B635-E7D5BF90CD8B Q36616905-4C6E22B8-589C-4C81-9DFD-233817AA29CE Q36677407-CE206AE2-8005-45D6-97C2-1E5A4719DA00 Q36891571-746ED9B2-4C55-4EEC-98C6-ED72430CA3C4 Q36964976-284FB534-A863-4287-AA84-B3B6880D9062 Q37063496-4626F4AE-888C-4877-9D80-F34C5DB877D1 Q37122717-E354C163-58F1-47D5-A0AF-D8B4750CCD03 Q37377316-26445ABB-72BF-48CB-87E7-C35D1CB12C76 Q38033672-F393DEF9-DBF6-479C-AAF7-06CBC8AFC595 Q38075152-EA690B28-4EEF-495B-A3DB-C16FC80A90E7 Q38168371-88502E9D-F6C5-4D93-AF83-2B679435479B Q38193533-C378FBA0-99DC-4C21-8B2A-6A56ACC824F8 Q38246305-997E46EB-F46E-464C-86A0-C28EE073E4C9 Q39012794-78A48772-ED46-4F35-9945-8897CEB075E8 Q39220133-8FBDAA36-1D30-4707-89DB-D8A0E21599F2 Q39377132-62CC73E9-0121-42AA-A3E6-20CD691A17E9 Q39547800-2D543761-299E-40C3-9182-8845334A0B0E Q40218344-FEAC04A5-7605-4B16-84DA-454D79D4F8A0 Q42323807-50F51F0C-E450-4281-825F-64EC5516EBAB

P2860

Angiogenesis inhibitors in clinical development; where are we now and where are we going?

http://www.wikidata.org/entity/Q35622433

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Angiogenesis inhibitors in clinical development; where are we now and where are we going?

@ast

Angiogenesis inhibitors in clinical development; where are we now and where are we going?

@en

type

label

Angiogenesis inhibitors in clinical development; where are we now and where are we going?

@ast

Angiogenesis inhibitors in clinical development; where are we now and where are we going?

@en

prefLabel

Angiogenesis inhibitors in clinical development; where are we now and where are we going?

@ast

Angiogenesis inhibitors in clinical development; where are we now and where are we going?

@en

P1433

Q35622433-EB4C7353-BCBD-46D7-AF73-E30DFE58F0B2

P1476

Q35622433-5054BAB6-3611-4FA8-B6E2-DB427E4CABFC

P2093

Q35622433-98150F97-996D-40A7-8006-2F200BDC61AD

P2860

Q35622433-0042A1CD-8210-4827-9814-9F68DA8B2324

Q35622433-0ADB4E7C-FBC6-489C-986D-851729146DAA

Q35622433-4ACE1DDB-2F55-4454-8B78-EDBD808C6F06

Q35622433-58EC5463-ECB5-491D-8B4A-1D38E9FBE6F2

Q35622433-88B08BE6-B42C-45B7-A61B-8ACAC8759188

Q35622433-A31B7404-0932-40A8-9E66-BD26A81806CE

Q35622433-AC134CFA-A6DB-4DB9-80CD-69B33E63A7E7

Q35622433-BA99464C-3550-4F65-B2EE-2C1337E04B10

Q35622433-C3D6E4A3-98EE-45FA-AF54-4AE0790CDCCF

Q35622433-CE88C22B-AB85-4AD1-A417-F2B443BA5B67

P2888

Q35622433-8E9E86CC-44B4-467E-9415-99D30354DCFC

P304

Q35622433-FFE383CA-E2ED-477F-AF6D-521631553394

P31

Q35622433-0E2687C8-F70C-4343-8875-C3ED82956AC9

Q35622433-60D10F09-12A2-414B-8346-F455FCFB819F

P356

Q35622433-065673E3-7E4D-4DEF-93CB-5C621441A4D1

P407

Q35622433-77F51C19-9B07-4B7B-8DE4-CFB4F9BD9178

P433

Q35622433-5A5716EA-D070-4B1A-9A6C-2BF511907291

P478

Q35622433-BB7BD2E0-EF27-4C29-9BF4-B241507BC169

P577

Q35622433-028FBC55-2411-47F2-9D89-DB4656CD7B38

Q35622433-DCC5D5F1-5317-4062-B08A-198FEBA89938

P5875

Q35622433-159BB452-F6E0-4CD9-BA2C-664FD4F7180E

P6179

Q35622433-C92CAF55-0E86-40BE-8BEA-1B12C3ED9F70

P698

Q35622433-C3B34FF3-C82D-46B5-AB29-6AD98B2C13D0

P921

Q35622433-6EE14D77-7547-4E06-9A22-F54A77CB0A4D

P932

Q35622433-C65D1CAB-1378-4BDE-AB9F-7039A579351A

P356

P1433

British Journal of Cancer

P1476

Angiogenesis inhibitors in clinical development; where are we now and where are we going?

@en

P2093

F A L M Eskens

http://www.w3.org/2001/XMLSchema#string

P2860

Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data.

Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors.

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.

5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study.

Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours.

Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3.

Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer.

Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation.

A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer.

Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily.

P2888

P304

1-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6601401

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

90

http://www.w3.org/2001/XMLSchema#string

P577

2004-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2004-01-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8930492

http://www.w3.org/2001/XMLSchema#string

P6179

1007664387

http://www.w3.org/2001/XMLSchema#string

P698

14710197

http://www.w3.org/2001/XMLSchema#string

P921

P932

2395335

http://www.w3.org/2001/XMLSchema#string